1. Home
  2. KALA vs UNCY Comparison

KALA vs UNCY Comparison

Compare KALA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.56

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$5.54

Market Cap

126.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALA
UNCY
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
126.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
KALA
UNCY
Price
$0.56
$5.54
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$31.50
$44.50
AVG Volume (30 Days)
20.4M
342.1K
Earning Date
11-19-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$3.71
52 Week High
$20.60
$11.00

Technical Indicators

Market Signals
Indicator
KALA
UNCY
Relative Strength Index (RSI) 37.14 45.63
Support Level $0.57 $5.69
Resistance Level $0.72 $6.30
Average True Range (ATR) 0.08 0.34
MACD 0.04 -0.07
Stochastic Oscillator 20.52 14.93

Price Performance

Historical Comparison
KALA
UNCY

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: